-
Foundation
Moderna is founded by Noubar Afeyan, Derrick Rossi, Robert Langer, and Kenneth Chien. -
$40 million funding
Moderna raises $40 million in Series A funding. -
Create a personalized cancer vaccine in mice
Moderna announces it has successfully used its mRNA technology to create a personalized cancer vaccine in mice. -
AstraZeneca Partnership
Moderna partners with AstraZeneca to develop mRNA-based therapies for cardiovascular, metabolic, and renal diseases as well as cancer. -
Company valuing $5 billion
Moderna raises $474 million in a Series F funding round, valuing the company at $5 billion. -
Moderna's mRNA-1647 vaccine for cytomegalovirus enters Phase 1 clinical trials
Moderna's mRNA-1647 vaccine for cytomegalovirus enters Phase 1 clinical trials -
The largest biotech IPO in history
Moderna becomes the largest biotech IPO in history, raising $604 million in its initial public offering. -
Clinical trials for for human metapneumovirus
Moderna's mRNA-1653 vaccine for human enters Phase 1 clinical trials. -
COVID-19 Clinical Trials
Moderna's COVID-19 vaccine enters clinical trials and is shown to be highly effective in preventing COVID-19. -
FDA approval for Emergency Use
Moderna's COVID-19 vaccine is granted Emergency Use Authorization by the FDA. -
Positive results in adolescents Phase 2/3 trial
Moderna announces positive results from a Phase 2/3 trial of its COVID-19 vaccine in adolescents. -
Moderna seasonal flu vaccine
Moderna announces it is developing a vaccine for the seasonal flu using mRNA technology. -
FDA approval for COVID-19 vaccine
Moderna receives FDA approval for its COVID-19 vaccine. -
Rare Genetic Diseases clinical trials
Moderna's mRNA-based therapies for rare genetic diseases enter clinical trials.
